[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632933":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":24,"locations":34,"responsibleParty":48,"collaborators":52,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":23,"enrollmentInfo":78,"targetDuration":23,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":23,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients diagnosed with Chronic Hepatitis B but Untreated","EXPERIMENTAL","A multicenter, prospective, dual-cohort (observational + interventional) study with a self-controlled baseline design. The study includes two core phases:\n\n1. Baseline cross-sectional survey: Characterize DBU patients, identify treatment barriers, and establish stratification variables for intervention.\n2. Prospective interventional cohort: Patients receive routine care plus four Union-Agent-driven services, with real-time data collection to evaluate treatment uptake and clinical outcomes.\n\nCore Services for Patients\n\n* Guideline-based personalized education;\n\n  * Standardized treatment recommendations; ③ Individualized medication reminders; ④ Semantic follow-up and risk assessment; ⑤ Automated scheduling: Reminders for routine reviews, lab tests, and appointment booking; support for uploading lab results for physician review.",[13],"Other: Agent Intelligence education",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Agent Intelligence education","Patients, while receiving usual care, will also receive four services from Union-Agent: (i) guideline-based educational modules tailored to patients' baseline knowledge of hepatitis B; (ii) personalized medication reminders with real-time adherence records; (iii) semantic follow-up that converts patient-reported symptoms into structured data and generates early risk alerts; and (iv) algorithm-driven referral suggestions aligned with China's three-tiered healthcare referral system.",[9],[20,21,22],"Agent Intelligence","education","antiviral treatment",null,[25,30],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Xin Zheng, Doctor of Philosophy","CONTACT","+86 18602724981","xinz@hust.edu.cn",{"name":31,"role":27,"phone":32,"phoneExt":23,"email":33},"Yanqin Du, Doctor of Medicine","+86 15871741706","yanqindu@163.com",[35],{"facility":36,"status":23,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":23},"Department of Infectious Disease, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430022","China","CN",{"type":43,"coordinates":44},"Point",[45,46],114.26667,30.58333,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Xin Zheng","Professor",[53,55,58,60,62,64,66],{"name":54,"class":6},"The First Affilated Hospital of the Medical College, Shihezi University",{"name":56,"class":57},"Taihe Hospital in Shiyan","UNKNOWN",{"name":59,"class":6},"Yichang Central People's Hospital",{"name":61,"class":6},"The Second Hospital of Anhui Medical University",{"name":63,"class":57},"Wuhan Jinyintan Hospital",{"name":65,"class":57},"Zigui County People's Hospital",{"name":67,"class":6},"Shanghai Zhongshan Hospital","100632933","union-fast-an-intelligent-agent-intervention-to-increase-antiviral-treatment-uptake-in-diagnosed-but-untreated-hepatitis-b-patients-100632933",false,"NCT07520123","Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients","Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients：A Multicenter Prospective Study","Union-FAST","Inclusion Criteria:\n\n* Aged ≥18 years with persistent HBsAg positivity for ≥6 months (diagnosed as chronic hepatitis B \\[CHB\\] per the latest Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis B).\n* Treatment-naïve to nucleos(t)ide analogues (NUCs), or previous NUC treatment with no medication for the past 6 months (diagnosed-but-untreated \\[DBU\\] status).\n* Capable of using a smartphone independently or with family member assistance.\n* Voluntarily provides written informed consent (electronic version) and agrees to study procedures and follow-up.\n\nExclusion Criteria:\n\n* Severe mental or cognitive impairment that impairs study cooperation.\n* Current participation in other interventional clinical trials that may influence HBV treatment decisions.\n* Inability to use a smartphone even with assistance.\n* Refusal to sign the informed consent form.","ALL","18 Years",{"count":79,"type":80},2000,"ESTIMATED","INTERVENTIONAL",[83],"NA","The World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB). However, as of 2024, only 26.1% of CHB infections globally have been diagnosed, and only 14.6% have received treatment, with treatment coverage falling far short of the target. A large number of patients are in a \"Diagnosed-but-Untreated (DBU)\" state, with major barriers including: low disease awareness, concerns about medication side effects, fragmented healthcare pathways, and poor physician-patient communication. Traditional hospital-based follow-up models are constrained by human resources and the capacity for health information system integration, making them difficult to scale widely in primary care settings.\n\nSupported by the National Key R\\&D Program of China, our team has successfully developed the world's first infectious disease agent (Union-Agent) after more than two years of research. This study aims to conduct a multicenter, prospective, two-cohort observational and interventional investigation to identify the reasons why DBU patients fail to initiate treatment and to explore whether an intervention using the Union-Agent can significantly increase the rate of antiviral treatment initiation within six months among DBU patients who meet the antiviral indications according to the 2022 Chinese guidelines for the prevention and treatment of chronic hepatitis B. The study hypothesizes that, compared to baseline, the Union-Agent can enable 50%-60% of treatment-eligible DBU patients to initiate antiviral therapy within six months.",[86],"Chronic Hepatitis B",[20,88,89,90],"chronic hepatitis B","hepatitis B virus","diagnosed-but-untreated","NOT_YET_RECRUITING","2026-04-06",{"date":94,"type":95},"2026-04-09","ACTUAL",{"date":97,"type":80},"2026-05-01",{"date":99,"type":80},"2027-12-31",{"name":5,"class":6},1]